Agenus Inc (NASDAQ:AGEN) shot up 9.5% during mid-day trading on Wednesday . The stock traded as high as $2.81 and last traded at $2.77. 3,628,000 shares changed hands during mid-day trading, an increase of 126% from the average session volume of 1,605,621 shares. The stock had previously closed at $2.53.
Several research firms recently issued reports on AGEN. BidaskClub downgraded Agenus from a “strong-buy” rating to a “buy” rating in a report on Tuesday, March 13th. ValuEngine upgraded Agenus from a “sell” rating to a “hold” rating in a report on Friday, February 23rd. Finally, Zacks Investment Research downgraded Agenus from a “hold” rating to a “sell” rating in a report on Tuesday, March 20th.
The company has a market capitalization of $288.08 million, a P/E ratio of -2.03 and a beta of 1.70. The company has a debt-to-equity ratio of -0.11, a current ratio of 2.16 and a quick ratio of 2.16.
Agenus (NASDAQ:AGEN) last released its earnings results on Monday, May 7th. The biotechnology company reported ($0.42) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.14). research analysts anticipate that Agenus Inc will post -1.54 EPS for the current year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AGEN. Point72 Asset Management L.P. acquired a new position in Agenus during the 1st quarter worth $16,342,000. Artal Group S.A. grew its stake in Agenus by 10.0% during the 1st quarter. Artal Group S.A. now owns 2,750,000 shares of the biotechnology company’s stock worth $12,953,000 after purchasing an additional 249,745 shares in the last quarter. Hudson Bay Capital Management LP grew its stake in Agenus by 60.7% during the 4th quarter. Hudson Bay Capital Management LP now owns 450,000 shares of the biotechnology company’s stock worth $1,467,000 after purchasing an additional 170,000 shares in the last quarter. UBS Group AG grew its stake in Agenus by 1,180.3% during the 1st quarter. UBS Group AG now owns 137,417 shares of the biotechnology company’s stock worth $647,000 after purchasing an additional 126,684 shares in the last quarter. Finally, RTW Investments LP boosted its position in shares of Agenus by 2.6% during the 4th quarter. RTW Investments LP now owns 4,329,816 shares of the biotechnology company’s stock worth $14,115,000 after acquiring an additional 111,296 shares in the last quarter. 45.60% of the stock is owned by hedge funds and other institutional investors.
Agenus Company Profile
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.